We also tested the efficiency of the GOLD-tracrRNA relative to the commercially available chemically modified tracrRNA (t0-IDT) by targeted cleavage adjacent to disease-associated positions from a database for human variations and phenotypes (ClinVar)21 associated with Rubinstein-Taybi syndrome (CREBBP), Stueve-Wiedemann syndrome (LIFR), pseudoxanthoma elasticum-like disorder (GGCX), and Wiedemann-Rautenstrauch syndrome (POLR3A). This evidence concerns the gene POLR3A and leukemia inhibitory factor receptor measurement.